Global drug major Ranbaxy Laboratories on Thursday announced the launch of its generic version of its much sought after cholesterol-lowering drug Lipitor in the U.S. market.
The announcement of the launch came following the final approval from the U.S. health regulator to manufacture the generic version of Lipitor at the Ranbaxy’s wholly owned Ohm Laboratories facility in New Brunswick, New Jersey, as well as market the product. “Ranbaxy Pharmaceuticals Inc, a wholly owned subsidiary of Ranbaxy Laboratories, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin and has launched the product in the U.S. market,” the company said in a statement issued here.
Ranbaxy CEO and Managing Director Arun Sawhney, referring to the latest development, said: “Atorvastatin helps millions of Americans manage healthy cholesterol levels and we are pleased to have received USFDA approval to manufacture and market a safe, effective, affordable and accessible alternative to branded Lipitor. We are committed to continuing to expand our portfolio of products offered in the U.S. market for the benefit of patients, prescribes and the U.S. healthcare system.”